Sera Prognostics, Inc.

Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.

อุตสาหกรรม

Medical - Diagnostics & Research

ภาคส่วน

Healthcare

สำนักงานใหญ่

US

ซีอีโอ

Zhenya Lindgardt

จดทะเบียนตั้งแต่

15 ก.ค. 2564

พนักงาน

72